Literature DB >> 19079814

A randomized cross-over study of a traditional Japanese medicine (kampo), yokukansan, in the treatment of the behavioural and psychological symptoms of dementia.

Katsuyoshi Mizukami1, Takashi Asada, Toru Kinoshita, Katsuaki Tanaka, Kazuki Sonohara, Ryuhei Nakai, Kiyoshi Yamaguchi, Haruo Hanyu, Kiyoshi Kanaya, Tetsuya Takao, Masakatsu Okada, Sumio Kudo, Hayato Kotoku, Masahiko Iwakiri, Hirofumi Kurita, Toshihiro Miyamura, Yosuke Kawasaki, Koji Omori, Kazumasa Shiozaki, Toshinari Odawara, Tatsuya Suzuki, Shizuru Yamada, Youichi Nakamura, Kenji Toba.   

Abstract

The effectiveness and safety of yokukansan (TJ-54), a traditional Japanese medicine (kampo) for the treatment of the behavioural and psychological symptoms of dementia (BPSD), were evaluated in 106 patients diagnosed as having Alzheimer's disease (AD) (including mixed-type dementia) or dementia with Lewy bodies. Patients were randomly assigned to group A (TJ-54 treatment in period I and no treatment in period II; each period lasting 4 wk) or group B (no treatment in period I and TJ-54 treatment in period II). BPSD and cognitive functions were evaluated using the Neuropsychiatric Inventory (NPI) and the Mini-Mental State Examination (MMSE), respectively. Activities of daily living (ADL) were evaluated using Instrumental Activities of Daily Living (IADL) in outpatients and the Barthel Index in in-patients. For the safety evaluation, adverse events were investigated. Significant improvements in mean total NPI score associated with TJ-54 treatment were observed in both periods (Wilcoxon test, p=0.040 in period I and p=0.048 in period II). The mean NPI scores significantly improved during TJ-54 treatment in groups A and B (p=0.002 and p=0.007, respectively) but not during periods of no treatment. Among the NPI subscales, significant improvements were observed in delusions, hallucinations, agitation/aggression, depression, anxiety, and irritability/lability. The effects of TJ-54 persisted for 1 month without any psychological withdrawal symptoms in group A. TJ-54 did not show any effect on either cognitive function or ADL. No serious adverse reactions were observed. The present study suggests that TJ-54 is an effective and well-tolerated treatment for patients with BPSD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19079814     DOI: 10.1017/S146114570800970X

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  54 in total

Review 1.  The role of phytochemicals in the treatment and prevention of dementia.

Authors:  Melanie-Jayne R Howes; Elaine Perry
Journal:  Drugs Aging       Date:  2011-06-01       Impact factor: 3.923

2.  Severe metabolic alkalosis, hypokalemia, and respiratory acidosis induced by the Chinese herbal medicine yokukansan in an elderly patient with muscle weakness and drowsiness.

Authors:  Shunsuke Yamada; Masanori Tokumoto; Yasuo Kansui; Yoshinobu Wakisaka; Yuji Uchizono; Kazuhiko Tsuruya; Hiroaki Ooboshi
Journal:  CEN Case Rep       Date:  2012-09-12

3.  Mother/offspring co-administration of the traditional herbal remedy yokukansan during the nursing period influences grooming and cerebellar serotonin levels in a rat model of neurodevelopmental disorders.

Authors:  Katsumasa Muneoka; Makiko Kuwagata; Tetsuo Ogawa; Seiji Shioda
Journal:  Cerebellum       Date:  2015-04       Impact factor: 3.847

4.  The blood-brain barrier permeability of geissoschizine methyl ether in Uncaria hook, a galenical constituent of the traditional Japanese medicine yokukansan.

Authors:  Sachiko Imamura; Masahiro Tabuchi; Hirotaka Kushida; Akinori Nishi; Hitomi Kanno; Takuji Yamaguchi; Kyoji Sekiguchi; Yasushi Ikarashi; Yoshio Kase
Journal:  Cell Mol Neurobiol       Date:  2011-03-26       Impact factor: 5.046

5.  Effect of Yokukansan for the Treatment of Idiopathic Rapid Eye Movement Sleep Behavior Disorder: A Retrospective Analysis of Consecutive Patients.

Authors:  Kentaro Matsui; Taeko Sasai-Sakuma; Jun Ishigooka; Katsuji Nishimura; Yuichi Inoue
Journal:  J Clin Sleep Med       Date:  2019-08-15       Impact factor: 4.062

6.  Efficacy and safety of yokukansan in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled trial (a Positive and Negative Syndrome Scale, five-factor analysis).

Authors:  Tsuyoshi Miyaoka; Motohide Furuya; Jun Horiguchi; Rei Wake; Sadayuki Hashioka; Masaya Tohyama; Norio Mori; Yoshio Minabe; Masaomi Iyo; Shyuichi Ueno; Sachiko Ezoe; Kenta Murotani; Syuzo Hoshino; Haruo Seno
Journal:  Psychopharmacology (Berl)       Date:  2014-06-13       Impact factor: 4.530

7.  Isoliquiritigenin is a novel NMDA receptor antagonist in kampo medicine yokukansan.

Authors:  Zenji Kawakami; Yasushi Ikarashi; Yoshio Kase
Journal:  Cell Mol Neurobiol       Date:  2011-06-21       Impact factor: 5.046

8.  Effects of geissoschizine methyl ether, an indole alkaloid in Uncaria hook, a constituent of yokukansan, on human recombinant serotonin 7 receptor.

Authors:  Toshiyuki Ueki; Akinori Nishi; Sachiko Imamura; Hitomi Kanno; Kazushige Mizoguchi; Kyoji Sekiguchi; Yasushi Ikarashi; Yoshio Kase
Journal:  Cell Mol Neurobiol       Date:  2012-09-12       Impact factor: 5.046

9.  Familial prion protein mutants inhibit Hrd1-mediated retrotranslocation of misfolded proteins by depleting misfolded protein sensor BiP.

Authors:  Sarah L Peters; Marc-André Déry; Andrea C LeBlanc
Journal:  Hum Mol Genet       Date:  2016-01-05       Impact factor: 6.150

10.  Geissoschizine methyl ether, an alkaloid from the Uncaria hook, improves remyelination after cuprizone-induced demyelination in medial prefrontal cortex of adult mice.

Authors:  Shoko Morita; Kouko Tatsumi; Manabu Makinodan; Hiroaki Okuda; Toshifumi Kishimoto; Akio Wanaka
Journal:  Neurochem Res       Date:  2013-11-06       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.